Press the l key to open the language menu.
Skip Main Navigation and go to Content

The retinal implant provides stimulation to induce visual perception in blind individuals.

Availability in North America

The Argus® II Retinal Prosthesis System ("Argus II") is currently offered in 22 cities across the U.S. and Canada to treat patients with late stage retinitis pigmentosa (RP). The Food and Drug Administration (FDA) approved Argus II in February, 2013 and Health Canada approved it in December, 2014. The Argus II is the first and only "bionic eye" to be approved in countries throughout the world, including the U.S. and Canada.

Current and future implant centers are located at nationally recognized and prestigious hospitals in:

Ann Arbor, MI Denver, CO Los Angeles, CA Rochester, NY
Atlanta, GA Durham, NC Miami, FL San Francisco, CA
Baltimore, MD Gainesville, FL Minneapolis, MN Montreal, QC, Canada
Boston, MA Honolulu, HI Northern NJ Toronto, ON, Canada
Chicago, IL Houston, TX Philadelphia, PA  
Cleveland, OH Long Island, NY Rochester, MN  

In order to make the Argus II therapy more widely accessible to patients with end-stage RP, the company will continue to actively identify additional centers across North America, while at the same time working to ensure adequate insurance coverage for the system and the medical activities surrounding the delivery of the therapy. Second Sight encourages interested patients and surgical centers to contact the company for more information.

For further information about our product in the US or to be put on a notification list, please call Second Sight Customer Service toll free at (855) 756-3703. We are located in Sylmar, California (Pacific time zone).

If you are an ophthalmologist that is interested in learning more about becoming an Argus II center please call Steve Okland, Commercial VP, Americas at (818) 833-5026